November 4, 2011
In its consolidated settlement of accounts for April-September announced on November 1, Astellas Pharma posted sales of ¥483.925 billion, +4.8% compared to the corresponding period of the previous year, driven by its mainline overactive bladder (OAB) treatment Vesicare (solifenacin). Operating,...read more